



ASX AND MEDIA RELEASE

Race signs two key consulting agreements

9 August 2016, Perth, Australia: Race Oncology Ltd (ASX: RAC) today announced that it had signed agreements with two key consultants involved in the Bisantrone development program: Dr Daniel Levy and Dr Kalidas Kale.

Dr Daniel Levy holds a PhD in organic chemistry from MIT and is a highly-experienced pharmaceutical scientist, who for the last six years has provided consultancy services to pharmaceutical companies, such as Race Oncology. More information is available about Dr Levy's consulting practice at delbiopharma.com. Previously he was a research scientist for several companies, including Scios, COR Therapeutics, Advanced Medicine and Ligand Pharmaceuticals. Dr Levy has been engaged by Race to coordinate all aspects of the manufacturing of Bisantrone, from manufacturing of the active pharmaceutical ingredient (API) through to final packaging and release for sale.

"Dan Levy adds a lot of value to our team," said Race Oncology CEO, Peter Molloy. "His expertise has already helped us define our timelines clearly and he will now drive the whole manufacturing program to ensure that we have final drug product ready to meet both our IND filing and NPP launch plans." The Company has previously stated that it intends to file an IND (Investigational New Drug) and launch a Named Patient Program in Europe to generate sales.

Dr Kalidas Kale is a US-based chemist, who has unique experience with Bisantrone. In addition to working as a research scientist at Bristol-Myers Squibb and Barr Laboratories, Dr Kale worked for five years at Lederle Laboratories, the company that originally developed Bisantrone. Between 1988 and 1993, he worked on developing improved dosage forms for Bisantrone and is very familiar with all the manufacturing and formulation around Bisantrone.

"Dr Kale has valuable knowledge about Bisantrone," said Mr Molloy. "Over the next several months, he will work with Dr Levy and our CSO, Dr John Rothman, to help expedite our formulation development and manufacturing and ensure we keep to our timelines."

About Race Oncology

Race Oncology Ltd is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company's first important asset is a chemotherapy drug, called Bisantrone, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrone and has secured Orphan Drug Designation in the US. The Company's goal is to complete final development of Bisantrone and bring this valuable cancer drug to market. Visit raceoncology.com for more information.

For more information, contact:

Peter Molloy
Managing Director
T: +61 (0) 3 9097 1656
M: +61 (0) 418 174 816